HBIO

Business Context and Reporting Period

Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2002
Business Overview: A global developer, manufacturer, and marketer of specialized scientific instruments used to accelerate drug discovery research. The company operates through direct sales, catalogs, and distributors (including Amersham Biosciences and PerkinElmer) across the U.S., Europe, and Asia.

Key Financial Metrics

Note: All figures in thousands except per share data. Net income for the three months ended Sep 30, 2002 was a loss of $82,000, while the nine-month period showed a profit of $1.7 million.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 20% ($2.15M) for the quarter and 33% ($9.5M) for the nine months compared to the prior year. Growth was driven by acquisitions (approx. 13-19% of increase) and new product introductions (spectrophotometers, plate readers).
• Profitability Turnaround: The company returned to profitability for the nine-month period ($1.7M net income) compared to a $4.8M loss in the same period in 2001. This was aided by the cessation of goodwill amortization under SFAS No. 142 and the absence of significant in-process R&D write-offs seen in 2001.
• Expense Management: Stock compensation expense decreased significantly to $971,000 for the nine months (down from $2.2M in 2001). However, restructuring expenses of $632,000 were recorded in Q3 2002 related to consolidating operations at Union Biometrica and Walden Precision Apparatus (WPA).
• Debt Reduction: Total debt decreased substantially. Current installments of long-term debt dropped from $3.89M to $1.01M, and long-term debt fell from $637k to $74k, primarily due to the repayment of debt from the SciePlas acquisition.

Guidance, Outlook, Risks, and Unusual Items

Management Commentary and Outlook

Management expects cash generated from operations and available capital to be sufficient for the foreseeable future. The company continues to pursue an acquisition strategy to expand its product line in niche markets. A stock repurchase program of up to $5 million was approved by the Board in November 2002.

Unusual Items and Contingencies

• Acquisitions: Completed the acquisition of Walden Precision Apparatus (WPA) in July 2002 and Genomic Solutions Inc. in October 2002 (subsequent event). The Genomic Solutions deal involved $9M cash and 3.2M shares.
• Legal Proceedings:
  • Harvard University: Ongoing trademark infringement lawsuit. The company won a partial summary judgment in May 2002 regarding the name "Harvard Apparatus" but faces remaining claims.
  • Paul D. Grindle: Arbitration regarding post-closing purchase price adjustments. The arbitrator ruled in favor of Harvard Bioscience in October 2002, dismissing all claims, though the former owner may challenge the decision.

Risks

• Integration Risk: Challenges in integrating Genomic Solutions and WPA, including potential disruption to operations and culture clashes.
• Customer Concentration: Significant reliance on the pharmaceutical and biotechnology industries, which are subject to funding fluctuations and patent expirations.
• Distributor Dependence: Approximately 30% of 2001 revenues came through Amersham Biosciences; termination of this agreement could materially impact the business.
• Goodwill Impairment: With $19.8M in goodwill (23% of total assets), future impairment charges could adversely affect net income.

Investor Verification Checklist

• Acquisition Integration: Verify the financial performance and integration progress of the recently acquired Genomic Solutions and WPA.
• Legal Resolution: Monitor the final status of the Harvard University trademark litigation and any potential appeal of the Grindle arbitration decision.
• Revenue Quality: Assess the sustainability of revenue growth, specifically the portion derived from new acquisitions versus organic growth.
• Goodwill Valuation: Review the annual impairment testing of the $19.8M goodwill balance, particularly given the company's history of acquisitions.
• Cash Flow Sustainability: Confirm that operating cash flows remain positive despite the cash outflows associated with the Genomic Solutions acquisition and ongoing R&D.